Renalys Pharma, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Renalys Pharma, Inc. - overview
Established
2024
Location
Chuo-ku, Tokyo, Japan
Primary Industry
Biotechnology
About
Founded in 2024 and based in Tokyo, Japan, Renalys Pharma, Inc. operates as a biopharmaceutical company that develops drugs for end-stage renal diseases. The company was founded by its CEO, BT Slingsby, and CFO, Takeshi Takahashi. In January 2024, Catalys Pacific and SR One formed Renalys Pharma, Inc.
Renalys Pharma offers a clinical-stage biotechnology platform that develops drugs for patients with renal diseases in Asian countries. The firm develops treatments for chronic kidney disease (CKD) and end-stage renal disease (ESRD) in Japan and Asia. The company’s product line includes sparsentan, an oral dual endothelin angiotensin receptor antagonist (DEARA), which is a non-immunosuppressive therapeutic that develops drugs for IgA nephropathy patients. The company plans to use the investment raised in January 2024 to expand its market reach locally and internationally.
Current Investors
SR One, Catalys Pacific, Sumitomo Mitsui Trust Bank
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals
Website
www.renalys.com/
Verticals
Manufacturing
Total Amount Raised
Subscriber access only
Renalys Pharma, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| LP Direct | Completed | Renalys Pharma, Inc. | - | ||||||||
| Company Formation | Completed | Renalys Pharma, Inc. | - |
Displaying 1 - 2 of 2
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.